Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science submitted its audited financial results for the quarter and full year ended March 31, 2025, approved at the board meeting on May 22, 2025. The board also recommended a final dividend of Rs. 4 per share (40% on face value of Rs. 10), to be paid within 30 days of AGM approval. Statutory auditor B S R & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated results. The auditor highlighted an Emphasis of Matter noting that FY24 results have been restated due to the NCLT-approved Scheme of Arrangement for the demerger of the CDMO and Soft Gelatin businesses, with a retrospective appointed date of April 1, 2024. Additionally, the merger of Strides Alathur Private Limited (formerly Vivimed Life Sciences) was accounted for retrospectively, restating prior period numbers accordingly. The consolidated results include 27 subsidiaries on an unaudited basis, as confirmed by the board.
Shareholders get a clean audit opinion plus a Rs. 4 per share dividend, which is a positive signal on profitability and cash generation. However, prior-year comparisons are not like-for-like due to the demerger and amalgamation restatements, so investors should focus on the restated FY25 numbers and management commentary rather than straight YoY growth metrics.